Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead
New York, Jan 20, 2026, 20:41 EST — Market closed. Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up. (Finviz) The update is crucial as Merck aims to expand its growth story beyond Keytruda,…